Description
Structure & Identity
Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist. Its sequence is based on the GIP peptide but tuned so that it activates both the GIP and GLP-1 receptors, and like Semaglutide it carries a fatty-acid chain that binds albumin to extend its active life. That dual-receptor design is the defining feature researchers study.
Research Background
Tirzepatide research is about dual incretin signaling, GIP and GLP-1 together.
- Dual-agonist characterization. Its original description introduced it as a novel dual GIP and GLP-1 receptor agonist, the foundation of the research interest [1].
- Biased signaling. Detailed pharmacology has described Tirzepatide as an imbalanced, biased agonist across the two receptors, a nuance researchers actively study [2].
- GIP-plus-GLP-1 rationale. Work on why adding GIP to GLP-1 matters has helped frame the dual-receptor approach [3].
These are research contexts rather than approved uses, and the peptide is intended for laboratory study.
Specifications
| Attribute | Value |
| Chemical name | Tirzepatide |
| Also Known As | (dual GIP/GLP-1 receptor agonist) |
| CAS number | 2023788-19-2 |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.5 g/mol |
| Length | 39 amino acids |
| Purity | ≥99% by reverse-phase HPLC |
| Length | 39 amino acids |
| Identity | Confirmed by ESI mass spectrometry |
| Physical form | Lyophilized powder |
| Appearance | White to off-white solid |
| Quantity | 15 mg per vial |
| Storage | -20°C, protected from light |
| Solubility | Soluble in bacteriostatic or sterile water (gentle mixing) |
| Classification | Research use only |
Storage & Handling
Store the sealed vial frozen at -20°C and shielded from light until use. After reconstitution, keep the solution refrigerated at 2-8°C and use it within about two weeks. As a large modified peptide, Tirzepatide benefits from being warmed to room temperature before opening and from being aliquoted so it is not frozen and thawed repeatedly.
Quality Assurance
Tirzepatide is produced under research-grade manufacturing controls and released only after independent verification. Purity is measured by reverse-phase HPLC and identity by mass spectrometry, with that work done by third-party laboratories such as Janoshik Analytical along with domestic US labs. A certificate of analysis is issued for each batch, so the results trace to the exact vial you receive.
Frequently Asked Questions
What is Tirzepatide?
Tirzepatide is a synthetic peptide that acts as a dual agonist at the GIP and GLP-1 receptors, the two main incretin pathways. It is studied in metabolic and receptor research and is supplied for research use only.
What is a “dual agonist”?
It means one molecule that switches on two different receptors. Tirzepatide activates both the GIP receptor and the GLP-1 receptor, whereas single agonists like Semaglutide activate only one.
How is Tirzepatide different from Semaglutide?
Semaglutide targets the GLP-1 receptor alone; Tirzepatide targets both GIP and GLP-1. That extra GIP activity is the main structural and pharmacological difference between the two.
What are GIP and GLP-1?
They are incretin hormones the gut releases after eating, both involved in metabolic signaling. Tirzepatide is designed to act on the receptors for both.
Is Tirzepatide FDA approved?
The Tirzepatide molecule is approved as a drug in defined clinical uses, but this listing is a research-use-only reference peptide, not for human or veterinary use.
What is Tirzepatide’s molecular weight?
It is a 39-amino-acid peptide with the formula C225H348N48O68, a molecular weight around 4813.5 g/mol, and CAS number 2023788-19-2.
How should Tirzepatide be stored?
Keep the powder frozen at -20°C and protected from light. After reconstitution for research, store at 2-8°C and use within about two weeks.
How is this Tirzepatide verified?
It is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab, and each batch ships with a certificate of analysis.
